Ernexa Therapeutics Inc. Proceeds from Issuance or Sale of Equity
Ernexa Therapeutics Inc. (ERNA) reported Proceeds from Issuance or Sale of Equity of $185.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOrSaleOfEquity · last filed 2026-08-06
- Ernexa Therapeutics Inc. proceeds from issuance or sale of equity for the quarter ending 2025-12-31 was $0.00.
- Ernexa Therapeutics Inc. proceeds from issuance or sale of equity for the quarter ending 2025-06-30 was $7.20M.
- Ernexa Therapeutics Inc. proceeds from issuance or sale of equity for the quarter ending 2014-09-30 was $915.75K.
- Ernexa Therapeutics Inc. proceeds from issuance or sale of equity for fiscal 2025 was $7.20M.
| Period end | Proceeds from Issuance or Sale of Equity | Proceeds from Issuance or Sale of Equity as first filed | Proceeds from Issuance or Sale of Equity 3 month | Proceeds from Issuance or Sale of Equity 6 month | Proceeds from Issuance or Sale of Equity 9 month | Proceeds from Issuance or Sale of Equity 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $185.00K 10-Q · filed 2026-08-06 | |||||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $7.20M 10-K · filed 2026-03-13 | ||||
| 2025-09-30 | $7.20M 10-Q · filed 2025-11-07 | |||||
| 2025-06-30 | $7.20M 10-Q · filed 2025-08-13 | |||||
| 2025-06-27 | $5.00K 10-Q · filed 2026-08-06 | $190.00K 10-Q · filed 2025-08-13 | ||||
| 2025-06-09 | $152.00K 10-Q · filed 2026-08-06 | $5.92M 10-Q · filed 2025-08-13 | ||||
| 2025-04-02 | $28.00K 10-Q · filed 2026-08-06 | $1.09M 10-Q · filed 2025-08-13 | ||||
| 2014-09-30 | $915.75K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $7.02M 10-Q · filed 2014-11-07 | ||||
| 2014-06-30 | $6.11M 10-Q · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |